<DOC>
	<DOCNO>NCT02720120</DOCNO>
	<brief_summary>This study two part evaluate safety , tolerability efficacy escalate single intravenous ( IV ) dose ocrelizumab compare placebo combination methotrexate participant moderate severe RA . Part 1 dose-escalation study , one follow dose level ocrelizumab [ 400 , 1000 , 1500 , 2000 milligram ( mg ) ] . In Part 2 , participant randomize explore tolerability efficacy dose show tolerated Part 1 .</brief_summary>
	<brief_title>A Study Ocrelizumab Participants With Moderate Severe Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Moderate severe RA least 6 month Positive serum rheumatoid factor ( &gt; /= 20 international unit per milliliter ) Current treatment RA outpatient basis Treatment failure one disease modify antirheumatic drug ( DMARD ) biologic , fail six agent include methotrexate Current treatment methotrexate least 12 week , stable dose Use highly effective contraception . Rheumatic autoimmune disease inflammatory joint disease , RA Concurrent treatment diseasemodifying antirheumatic drug ( DMARD ) ( methotrexate ) antitumor necrosis factor ( TNF ) alfa biologic therapy Treatment investigational drug within 4 week screen Previous treatment celldepleting therapy , IV gammaglobulin , intraarticular parenteral corticosteroid , receipt live/attenuated vaccine prior screen Previous treatment rituximab anticluster differentiation 20 ( CD20 ) agent History severe allergic anaphylactic reaction humanize monoclonal antibody Known active bacterial , viral fungal infection History active tuberculosis primary secondary immunodeficiency History concomitant diseases cardiovascular disease , nervous system , pulmonary disease , renal , hepatic , endocrine gastrointestinal disorder Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>